Table 3. Characteristics and conclusions of the eight studies included in this systematic review.

PD - Parkinson's disease; L-DOPA - levodopa; MAOB-I - monoamine oxidase type-B inhibitor

Author	Year	Study design	Modality of treatment/factors investigated	Conclusion
Giossi et al. [1]	2021	Systematic review and meta-analysis	Safinamide	Safinamide was found efficacious in PD patients with motor fluctuations
Ahmad et al. [8]	2019	Systematic review and meta-analysis	Safinamide	Provided class 1 evidence regarding the role of safinamide as an adjunct medication in patients with PD with motor fluctuations
Borgohain et al. [9]	2013	Randomized clinical trial	Safinamide as an add-on to L-DOPA in PD patients with motor fluctuations	The drug increased total "on time," decreased "off-time," and improved parkinsonism
Binde et al. [14]	2020	Meta-analysis	Dopamine agonists and MAOB-Is	This study found that safinamide was not effective in comparison to placebo. Selegiline was found to be most effective as an add-on to L-DOPA
Schapira et al. [10]	2017	Randomized clinical trial	Safinamide as an add on to L-DOPA	This study concluded that the drug in combination with L-DOPA improves the studied outcomes: off time, on time without dyskinesia
Hattori et al. [7]	2020	Randomized control trial	Safinamide as a L-DOPA adjunct	The conclusions of this study found safinamide to be safe and increase "on time," and alleviate symptoms in PD patients with wearing-off
Huang et al. [4]	2021	Meta-analysis	MAOB-Is	This study found that MAOB-Is decrease the severity of depressive episodes in PD patients
Qureshi et al. [5]	2018	Systematic review and meta-analysis	Therapies for pain	From the therapies studied in this research, safinamide was found to be most effective in decreasing pain in PD patients